CAL
PPH icon

Capital Analysts LLC’s VanEck Pharmaceutical ETF PPH Stock Holding History

Capital Analysts LLC’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25K Hold
232
– – ﹤0.01% 1118
2026
Q1 		$24K Hold
232
– – ﹤0.01% 1090
2025
Q4 		$24K Hold
232
– – ﹤0.01% 1071
2025
Q3 		$21K Hold
232
– – ﹤0.01% 1070
2025
Q2 		$20K Hold
232
– – ﹤0.01% 1019
2025
Q1 		$21K Hold
232
– – ﹤0.01% 989
2024
Q4 		$20K Hold
232
– – ﹤0.01% 944
2024
Q3 		$22K Buy
+232
New +$22K ﹤0.01% 890

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Capital Analysts LLC's PPH Position: Q2 2026 in Review

Capital Analysts LLC held its VanEck Pharmaceutical ETF (PPH) position steady in Q2 2026 at 232 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #1118.

Capital Analysts LLC first reported a position in PPH in Q3 2024 and has held it in 8 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • Capital Analysts LLC held 232 shares of VanEck Pharmaceutical ETF worth $25K as of Q2 2026.
  • Capital Analysts LLC left its VanEck Pharmaceutical ETF share count unchanged in Q2 2026.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1118 holding.
  • Capital Analysts LLC first reported a position in VanEck Pharmaceutical ETF in Q3 2024 and has held it in 8 quarters since.
  • 148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.